Form 8-K - Current report:
SEC Accession No. 0001104659-25-096047
Filing Date
2025-10-02
Accepted
2025-10-02 16:01:22
Documents
12
Period of Report
2025-09-28
Items
Item 2.05: Cost Associated with Exit or Disposal Activities

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2527561d1_8k.htm   iXBRL 8-K 30190
  Complete submission text file 0001104659-25-096047.txt   197446

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA syn-20250928.xsd EX-101.SCH 3041
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE syn-20250928_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syn-20250928_pre.xml EX-101.PRE 22377
14 EXTRACTED XBRL INSTANCE DOCUMENT tm2527561d1_8k_htm.xml XML 3692
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12584 | Film No.: 251368818
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)